Thomas Harder Email & Phone Number

My early cell biological work critically contributed to the notion that locally coalesced membrane raft domains function as platforms for membrane-proximal cell activities, like surface receptor signaling or cytoskeleton-membrane interactions. Based on this concept research teams which I led at the Basel Institute for Immunology and at the Sir William Dunn School of Pathology at the University of Oxford, characterized cell biology, biochemistry, biophysics, and immunology of plasma membrane rafts which control activities of T cells.Consequent translation of this concept toward medical application defined T-cell plasma membrane rafts as target for a regulatory signal constellation which induces a dormant state in resting T cells under which all T cell responses to activating TCR stimulus are comprehensively suppressed. Unique action of “T-cell Silencer” biologics is protected by Patent EP2878308 “Agents and methods for the suppression of T cell activation” of which I am proprietor. Biotech Start-up TRANQUIL IMMUNE will develop “T cell Silencer” biologics toward desperately needed treatment of pathogenic T cell activation in autoimmunity, inflammation, allergy, and transplant rejection.Spezialgebiete: Molecular Immunology, Systems Biology of plasma membrane domains engaged in T cell activation, Regulation of T cell activity

Listed skills include Biochemistry, Immunology, Pathology, Cell Biology, and 6 others.